Jay Herath/loyno.edu
Mar 24, 2026, 02:50
Jay Herath: Fitusiran Advancing Hemophilia Care Beyond Factor Replacement
Jay Herath, Professor of the Practice at Loyola University, shared a post on LinkedIn:
“Qfitlia (fitusiran), approved in 2025, is a first-in-class siRNA therapy that treats hemophilia A and B by targeting antithrombin-III mRNA in the liver.
Instead of replacing missing clotting factors (Factor VIII or IX), it reduces antithrombin levels, restoring the body’s ability to generate thrombin and form stable blood clots.”
Stay updated with Hemostasis Today.
-
Jun 24, 2026, 17:36Paul Whiteley: Neurodevelopmental and Autism Risks in Fetal and Neonatal Alloimmune Thrombocytopenia
-
Jun 24, 2026, 17:22Kavitha Dev: A Low Platelet Count Isn’t Always Critical, But It Should Never Be Ignored
-
Jun 24, 2026, 17:04Recurrent Cervical Internal Carotid Vasospasm Linked to Autosomal Recessive PTGIS Defect – International Journal of Stroke
-
Jun 24, 2026, 16:49Gaurav Kharya: Bridging the Gap in Safe Blood Access for Patients Who Can’t Wait
-
Jun 24, 2026, 16:40William Wallace: Vitamin C and Collagen Work as One Biological System
-
Jun 24, 2026, 16:32Arlindo Nascimento de Lemos Junior: Thrombus Echogenicity as a Predictor of Post-Thrombotic Syndrome Severity After DVT
-
Jun 24, 2026, 16:09Jimi Olaghere: The Future of Sickle Cell Disease Research Starts With Collaboration
-
Jun 24, 2026, 16:03Von Willebrand Disease as a Common Yet Under-Recognised Bleeding Disorder – EHC
-
Jun 24, 2026, 15:57Maia Meier: Women with Bleeding Disorders Reach the Summit of Mont Blanc